

CASSIE CHANG

Partner·Beijing

+86 10 5769 0043

cassie.chang@fangdalaw.com

PRACTICE AREA

MS CHANG SPECIALIZES IN CAPITAL MARKETS, M&A, PRIVATE EQUITY INVESTMENT, FOREIGN DIRECT INVESTMENT AND GENERAL CORPORATE.

Education

- China University of Political Science and Law, LL.M.
- China University of Political Science and Law, LL.B.

Professional Qualification

- Admitted to practice in the PRC

REPRESENTATIVE MATTERS AND CASES

- Represented Innocare Pharma Limited in its IPO on the Sci-Tech Board of the Shanghai Stock Exchange
- Represented BeiGene in its IPO on the Sci-Tech Board of the Shanghai Stock Exchange
- Represented Megvii in its IPO on the Sci-Tech Board of the Shanghai Stock Exchange
- Represented XPENG Inc. in its IPO on the HKEX
- Represented BeiGene in its IPO on the HKEX
- Represented Cheshi Holdings Limited in its IPO on the HKEX
- Represented Kingsoft Cloud Holdings Limited in its IPO on the NASDAQ
- Represented XPENG Inc. in its IPO on the NYSE
- Represented Jianpu Technology Inc. (Rong360) in its IPO on the NYSE
- Represented the underwriters Citigroup, Deutsche Bank Securities, AMTD, China Merchants Securities (HK), and Tiger Brokers in connection with the IPO of UP Fintech Holding Limited on the NASDAQ
- Represented the underwriter Rodman & Renshaw in connection with the IPO of Beyond Spring Inc. on the NASDAQ
- Represented the underwriters Morgan Stanley and J.P. Morgan in the Kingsoft Corporation Limited issuance of HK$3.1 billion in convertible bonds due 2025
- Represented Taikang, China Life, Pingan Life and other insurance companies in equity investments and fund investments in Dingdang Healt, an industrial fund of Sino-Ocean Group, Wuhan Lichu, STARTDT, Huadian New Energy Group, etc.
- Acted as legal advisor on general corporate affairs for listed companies including Jianpu (Rong360), Cango, Chindata, Xpeng and Kingsoft Cloud